Dr. Miner’s research focuses on patient-centered outcomes after surgery for advanced malignancy. He has published extensively on palliative surgical procedures and emphasizes symptom management and quality of life in patients with advanced cancer.

Dr. DeNardo is an expert in pediatric solid tumors and adolescent/young adult sarcomas. He directs the pediatric solid tumor program at Hasbro Children’s Hospital and the sarcoma program at Lifespan Cancer Institute. His research focuses on developmental therapeutics, including early-phase clinical trials of novel therapies. Dr. DeNardo is an active member of ASCO, ASPHO, COG, and the Connective Tissue Oncology Society.

Dr. Qureshi is chief of dermatology at Rhode Island Hospital and chair of dermatology at the Warren Alpert Medical School. His research includes teledermatology, skin cancer, vector-borne illnesses, and psoriasis. He has received multiple awards for mentorship and service and is a member of leading professional societies, including the Society for Investigative Dermatology and the American Association for Cancer Research.

Translational Research Disease Groups (TRDGs) provide a regular forum for advancing translational cancer research and fostering collaboration across disciplines. Eight TRDGs have been established at the Legorreta Cancer Center, each organized around a specific cancer type.

The Sarcoma & Skin Cancer TRDG brings together a multidisciplinary team of researchers and clinicians, including experts in:

• Hematology/oncology, radiation oncology, and surgical oncology
• Pathology, cancer biology, genetics, population science, biostatistics, and bioinformatics
• Fellows, residents, and student trainees

Our meetings create opportunities to:

• Develop and prioritize new translational research directions
• Share resources and expertise across Brown and affiliated hospitals
• Launch collaborations that can lead to pilot funding, extramural grant applications, and publications in high-impact journals
• Advance investigator-initiated clinical trials and translational protocols

TRDGs meet every 2–3 months, typically at the Brown University Molecular Medicine Building (70 Ship Street) or at an affiliated hospital site. Meetings feature a mix of roundtable discussions and designated speakers, with ample time for feedback and collaborative planning. Minutes are shared internally with group members.

Membership is open and evolving. We welcome faculty, fellows, residents, and students with an interest in translational breast cancer research to join our efforts.

• Review ongoing translational research and investigator-initiated trials
• Identify collaboration opportunities based on current science and feasibility
• Discuss biomarkers, tumor signaling pathways, and drug development strategies
• Exchange information on funding opportunities (e.g., P01s, SPOREs, or other translational grants)
• Highlight progress through focused presentations by investigators or subgroups
• Leverage institutional resources (genomics, tissue banks, clinical trial infrastructure, tumor boards)
• Engage trainees and early-career researchers in translational projects
• Form working groups to advance projects toward new protocols, grant submissions, and publications

Contact

For more information or to join the Sarcoma and Skin Cancer TRDG, please contact Attila Seyhan, PhD.